BiotechTube

GC1008 + GC1008 + GC1008 + GC1008

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Segmental Glomerulosclerosis

Conditions

Focal Segmental Glomerulosclerosis

Trial Timeline

May 1, 2007 → Feb 1, 2010

NCT ID
NCT00464321

About GC1008 + GC1008 + GC1008 + GC1008

GC1008 + GC1008 + GC1008 + GC1008 is a phase 1 stage product being developed by Sanofi for Focal Segmental Glomerulosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00464321. Target conditions include Focal Segmental Glomerulosclerosis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00464321Phase 1Completed

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
85
DapagliflozinAstraZenecaApproved
85
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
52
CCX140-BAmgenPhase 2
51
PF-06730512PfizerPhase 2
51
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
84
VX-147Vertex PharmaceuticalsPhase 2
51
VX-147Vertex PharmaceuticalsPhase 1
32
IXPVertex PharmaceuticalsPhase 1
32
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
51
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
51
VivaglobinCSLPhase 2
51
UCB0942UCBPhase 2
49
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
82
Brivaracetam + BrivaracetamUCBPhase 2
49
LacosamideUCBPhase 2
49
UCB0942 + UCB0942 + PlaceboUCBPhase 2
49
LacosamideUCBPre-clinical
20
ARGX-117ArgenxPhase 2
49
Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
74

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84